NUWELLIS INC. -,0001 (22SA.F)
Chart Events
Performance Outlook
| Previous Close | 4.3300 |
| Open | 4.4600 |
| Bid | 4.5300 x N/A |
| Ask | 4.6600 x N/A |
| Day's Range | 4.4600 - 4.4600 |
| 52 Week Range | 4.3100 - 164.0000 |
| Volume | |
| Avg. Volume | 145 |
| Market Cap | 2.464M |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics
MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option for acute decompensated heart failure (ADHF) patients who are resistant to diuretics or who have a history of multiple hospitalizations
- GlobeNewswire
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS, March 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), today announced that, effective February 23, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to six individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approve
- GlobeNewswire
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results
Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 GrowthMINNEAPOLIS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2022. Revenue of $2.3 million for the fourth quarter 2022, a 42% increase over the prior-year period. Full year revenue of $8.5 million, an 8% increase over 2021.G
